PBMs typically receive a portion of rebates paid by drug manufacturers, the majority of which are passed back to the payer as an incentive to prefer a drug on a formulary. PBMs may also retain revenue ...

The Centers for Medicare & Medicaid Services has announced the selection of 15 prescription drugs for the third cycle of the ...

The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay ...

List includes medications for diabetes, cancer, arthritis, and more ...

Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of federal price negotiations that could lower prices for Medicare patients.

Negotiations Will Occur in 2026 With Negotiated Prices Effective in 2028.8, 2026 - On Tuesday, the Centers for Medicare & ...

CMS has announced that the new cycle of drug price negotiations by Medicare will include big-name drugs for diabetes and HIV/AIDS, as well as Botox injections. 1,2 The 15 high-cost prescription drugs ...

The CMS has unveiled the 15 high-cost medications selected for the next phase of the Medicare Drug Price Negotiation Program.

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.

CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...

The selected medications treat a range of conditions, including cancer, psoriatic arthritis, and human immunodeficiency virus type 1 infection.